Mehmet KARADAĞ, R.Oktay GÖZÜ, Ercüment EGE, Zekiye YAVUZ, Esra UZASLAN, Ahmet URSAVAŞ, Yeşim Ozarda ILÇOL

Obstrüktif uyku apne sendromlu hastalarda homosistein düzeyleri

Obstrüktif uyku apne sendromu (OUAS) olan hastalarda, kardiyovasküler hastalıkların gelişim mekanizması tam olarak bilinmemektedir. Homosisteinin ateroskleroz gelişimindeki rolü son 10 yılda iyi tanımlanmıştır. Bu çalışmadaki amacımız, OUAS ile kontrol grubunun serum homosistein düzeylerini karşılaştırmaktır. Bu prospektif çalışmaya, yaş, cinsiyet, sigara, beden kitle indeksi ve koroner arter hastalığı (KAH) açısından benzer özellikte, 62 OUAS ve 12 kontrol olgusu dahil edildi. Serum homosistein düzeyi, OUAS’ta kontrol grubuna göre anlamlı düzeyde yüksekti (13.5 ± 6.0 µmol/L, 10.2 ± 2.9 µmol/L, p= 0.03), Lojistik regresyon analizinde, serum homosistein düzeyi yüksekliği için OUAS (Odds ratio: 9.08 %95 GA 2.347-35.120; p= 0.001), yaş, sigara, diyabet ve KAH’dan bağımsız risk faktörü olarak saptandı. OUAS hastalarında kardiyovasküler hastalıkların gelişiminde, homosisteinin önemli bir faktör olabileceği sonucuna vardık.

Homocysteine levels in patients with obstructive sleep apnea syndrome

The exact mechanism of development of cardiovascular disease in patients with obstructive sleep apnea syndrome (OSAS) remains to be unknown. The role of homocystein in atherosclerotic disease process has become well established over the past ten years. Our aim was to study to compare homoscysteine levels between OSAS and control levels. Sixty-two subjects with OSAS and twelve similar controls in age, gender, body mass index, smoking and coronary heart disease were included in this prospective study. Serum levels of homocysteine (13.5 ± 6.0 µmol/L vs. 10.2 ± 2.9 µmol/L, p= 0.03) in the OSAS group were significantly greater than those in the control group. Logistic regression analyses showed that OSAS (Odds ratio: 9.08 95% CI 2.347-35.120; p= 0.001) was independent risk factors for high levels of serum homocysteine in age, smoking status, diabetes mellitus and coronary heart disease. We conclude that homocysteine may be an important factor for development of cardiovascular disease in patients with OSAS.

PDF

___

1. Bixler EO, Vgontzas AN, Lin HM, et al. Prevalence of sleep disorders breathing in women; effects of gender. Am J Respir Crit Care Med 2001; 163: 608-13.
2. Hedner J, Grote L. Cardiovascular concequences of obstructive sleep apnea. Eur Respir Mon 1998; 10: 227-65.
3. Andreas S, Schulz R, Werner G, et al. Prevalence of obstructive sleep apnea in patients with coronary artery disease. Coron Artery Dis 1996; 7: 541-5.
4. Peker Y, Hedner J, Norum J, et al. Increased incidens of cardiovascular disease in middle-aged men with obstructive sleep apnea: A 7-year follow-up. Am J Respir Crit Care Med 2002; 166: 159-65.
5. Wilcox I, Mcnamara SG, Collins FL, et al. “Syndrome Z”: The interaction of sleep apnea, vascular risk factors and heart disease. Thorax 1998; 53(Suppl 3): 25-8.
6. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J 1999; 138(5 Pt 2): 419-20.
7. Ciftci TU, Kokturk O, Bukan N, Bilgihan A. The relationship between serum cytokine levels with obesity and obstructive sleep apnea syndrome. Cytokine 2004; 28: 87-91.
8. El-Solh AA, Mador MJ, Sikka P, et al. Adhesion molecules in patients with coronary artery disease and moderate-tosevere obstructive sleep apnea. Chest 2002; 121: 1541-7.
9. Tsao PS, Buitrago R, Chan JR, Cooke LP. Fluid flow inhibits endothelial adhesiveness. Nitric oxide and transcriptional regulation of VCAM-1. Circulation 1996; 94: 1682-9.
10. Hanker LA, Slichter SJ, Scott CR, Ross R. Homocysteinemia: Vascular injury and arterial thrombosis. N Engl J Med 1974; 291: 537-43.
11. Hankey GJ, Eikelboom JW, Ho WK, van Bockxmeer FM. Clinical usefulness of plasma homocysteine in vascular disease. MJA 2004; 181: 314-8.
12. Ursavaş A, Göktaş K, Sütçügil L, Özgen F. Obstrüktif uyku apne sendromlu hastalarda obezite ve kardiyovasküler hastalıkların değerlendirilmesi. Toraks Dergisi 2004;5: 79-83.
13. Mooe T, Rabben T, Wiklund U, et al. Sleep-disordered breathing in men with coronary artery disease. Chest 1996; 109: 659-63.
14. Mooe T, Rabben T, Wiklund U, et al. Sleep-disordered breathing in women occurence and association with coronary disease. Am J Med 1996; 101: 251-6.
15. Hatipoğlu U, Rubinstein I. Inflammation and obstructive sleep apnea syndrome pathogenesis: A working hypothesis. Respiration 2003; 70: 665-71.
16. Lavie L. Obstructive sleep apnoea syndrome- an oxidative stress disorder. Sleep Medicine 2003; 7: 35-51.
17. Loscalzo J. The oxidant stress of hyperhomocysteinemia. J Clin Invest 1996; 98: 5-7.
18. Stühlinger MC, Oka RK, Graf EE, et al. Endothelial dysfunction induced by hyperhomocysteinemia: Role of asymmetric dimethylarginin. Circulation 2003; 108: 933-8.
19. Nygard O, Nordrehaug JE, Refsum H, et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337: 230-7.
20. Lavie L, Perelman A, Lavie P. Plasma homocysteine levels in obstructive sleep apnea association with cardiovascular morbidity. Chest 2001; 120: 900-8.
21. Köktürk O, Çiftçi TU, Mollarecep E, Çiftçi B. Serum homocysteine levels and cardiovascular morbidity in obstructive sleep apnea syndrome. Respir Med 2006; 100:536-41.
22. Can M, Açıkgöz Ş, Mungan G, et al. Serum cardiovascular risk factors in obstructive sleep apnea. Chest 2006;129: 233-7.
23. Otake K, Delaive K, Walid R, et al. Cardiovascular medication use in patients undiagnosed obstructive sleep apnea. Thorax 2002; 57: 417-22.
24. Jordan W, Berger C, Cohrs S, et al. CPAP- therapy effectively lowers serum homocysteine in obstructive sleep apnea syndrome. J Neural Transm 2004; 111: 683-9.
25. Svatikova A, Wolk R, Magera MJ, et al. Plasma homocysteine in obstructive sleep apnea. European Heart Journal 2004; 25: 1325-9.